Oncternal Therapeutics (ONCT) Competitors $0.53 0.00 (0.00%) (As of 12/31/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ONCT vs. ELAB, APM, EGRX, PPBT, MBRX, CANF, ONVO, PRTG, HOTH, and IMCCShould you be buying Oncternal Therapeutics stock or one of its competitors? The main competitors of Oncternal Therapeutics include Elevai Labs (ELAB), Aptorum Group (APM), Eagle Pharmaceuticals (EGRX), Purple Biotech (PPBT), Moleculin Biotech (MBRX), Can-Fite BioPharma (CANF), Organovo (ONVO), Portage Biotech (PRTG), Hoth Therapeutics (HOTH), and IM Cannabis (IMCC). These companies are all part of the "pharmaceutical products" industry. Oncternal Therapeutics vs. Elevai Labs Aptorum Group Eagle Pharmaceuticals Purple Biotech Moleculin Biotech Can-Fite BioPharma Organovo Portage Biotech Hoth Therapeutics IM Cannabis Oncternal Therapeutics (NASDAQ:ONCT) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations. Which has better valuation and earnings, ONCT or ELAB? Elevai Labs has higher revenue and earnings than Oncternal Therapeutics. Oncternal Therapeutics is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncternal Therapeutics$790K1.97-$39.48M-$11.69-0.05Elevai Labs$2.45M2.42-$4.30M-$62.00-0.04 Do analysts rate ONCT or ELAB? Oncternal Therapeutics presently has a consensus target price of $10.00, suggesting a potential upside of 1,798.97%. Given Oncternal Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Oncternal Therapeutics is more favorable than Elevai Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncternal Therapeutics 0 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.25Elevai Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community prefer ONCT or ELAB? Oncternal Therapeutics received 32 more outperform votes than Elevai Labs when rated by MarketBeat users. CompanyUnderperformOutperformOncternal TherapeuticsOutperform Votes3225.40% Underperform Votes9474.60% Elevai LabsN/AN/A Do insiders & institutionals believe in ONCT or ELAB? 16.0% of Oncternal Therapeutics shares are held by institutional investors. Comparatively, 22.2% of Elevai Labs shares are held by institutional investors. 11.2% of Oncternal Therapeutics shares are held by insiders. Comparatively, 1.3% of Elevai Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is ONCT or ELAB more profitable? Elevai Labs has a net margin of -223.41% compared to Oncternal Therapeutics' net margin of -1,599.95%. Elevai Labs' return on equity of -124.93% beat Oncternal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oncternal Therapeutics-1,599.95% -177.58% -131.30% Elevai Labs -223.41%-124.93%-85.10% Does the media prefer ONCT or ELAB? In the previous week, Elevai Labs had 4 more articles in the media than Oncternal Therapeutics. MarketBeat recorded 5 mentions for Elevai Labs and 1 mentions for Oncternal Therapeutics. Oncternal Therapeutics' average media sentiment score of 0.00 beat Elevai Labs' score of -0.25 indicating that Oncternal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oncternal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Elevai Labs 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryElevai Labs beats Oncternal Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Oncternal Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCT vs. The Competition Export to ExcelMetricOncternal TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.56M$6.57B$5.16B$8.95BDividend YieldN/A2.96%4.96%4.12%P/E Ratio-0.0510.6687.2717.08Price / Sales1.97174.961,127.49120.08Price / CashN/A57.1443.2637.90Price / Book0.055.115.035.01Net Income-$39.48M$150.98M$120.45M$226.21M7 Day PerformanceN/A-1.06%-0.41%-0.01%1 Month PerformanceN/A-6.41%15.48%1.00%1 Year Performance-95.25%1.30%27.29%16.38% Oncternal Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCTOncternal Therapeutics1.5392 of 5 stars$0.53flat$10.00+1,799.0%N/A$1.56M$790,000.00-0.0530ELABElevai Labs0.1048 of 5 stars$2.40-1.6%N/A-99.4%$6.21M$2.45M-0.0418News CoverageGap UpAPMAptorum Group2.2264 of 5 stars$1.19+10.2%N/A+14.3%$6.17M$431,378.000.0030News CoveragePositive NewsGap UpTrading HaltedEGRXEagle Pharmaceuticals0.926 of 5 stars$0.45-10.0%N/A-90.4%$5.84M$257.55M0.00134Analyst ForecastPPBTPurple Biotech1.6615 of 5 stars$4.30-1.4%$33.00+667.4%N/A$5.72MN/A-0.4920Gap DownMBRXMoleculin Biotech2.1796 of 5 stars$1.77+7.3%$24.00+1,255.9%-86.8%$5.65MN/A0.0020Analyst ForecastGap UpCANFCan-Fite BioPharma2.2828 of 5 stars$1.56-1.3%$14.00+797.4%-26.1%$5.52M$667,000.00-0.878Analyst ForecastNews CoverageONVOOrganovo0.1062 of 5 stars$0.35-3.9%N/A-58.6%$5.42M$103,000.00-0.3320Gap UpPRTGPortage Biotech0.4388 of 5 stars$5.12-2.7%N/A-85.8%$5.37MN/A-0.126Gap DownHOTHHoth Therapeutics3.3755 of 5 stars$0.78+0.3%$3.50+351.0%-48.0%$5.36MN/A-0.594IMCCIM Cannabis0.9175 of 5 stars$2.34-4.1%N/A+8.8%$5.22M$51.39M-0.69340Positive NewsGap Down Related Companies and Tools Related Companies ELAB Alternatives APM Alternatives EGRX Alternatives PPBT Alternatives MBRX Alternatives CANF Alternatives ONVO Alternatives PRTG Alternatives HOTH Alternatives IMCC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCT) was last updated on 1/2/2025 by MarketBeat.com Staff From Our Partners3 CENT Crypto to Explode December 16th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredI was wrong. Dead wrong. Something is stirring deep in Silicon Valley. My team and I have been watching the tech markets closely. ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredApple feeling the heat from NvidiaNvidia has moved on to the next frontier of AI it intends to dominate. And we believe the three companies p...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncternal Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
